Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients With Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy (ACT-EARLY OLE)

NCT07116473 is registered in ClinicalTrials.gov with Eidos Therapeutics, a BridgeBio company as lead sponsor.

NCT NCT07116473
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07116473 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients With Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy (ACT-EARLY OLE)
Lead sponsor
Eidos Therapeutics, a BridgeBio company
Phase
Phase 3
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
December 31, 2037
Enrollment
250 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

amyloid cardiomyopathy, amyloid cardiomyopathy, transthyretin-related, amyloidogenic transthyretin (attr) amyloidosis, amyloidosis, amyloidosis in transthyretin (ttr), amyloidosis, familial, amyloidosis, hereditary, transthyretin-related, cardiomyopathies, heart disease, polyneuropathies